Product Information |
Product name |
Adenosine triphosphate disodium / ATP |
Synonyms |
Adenosine-5'-triphosphate disodium trihydrate; 5'-ATP-Na2; ADENOSINE-5'-TRIPHOSPHATE DISODIUM SALT HYDR.,CALCIUM FREE; Adenosine-5'-triphosphate disodium salt hydrate,water; disodium adenosine 5'-triphosphate trihydrate; |
CAS No. |
987-65-5 |
Molecular Formula |
C10H16N5O13P3.3H2O.2Na |
Molecular Weight |
607.21 |
Molecular Structure |
|
Quality Standard |
99% up by HPLC |
Appearance |
White to off-white powder |
COA of Adenosine
triphosphate disodium / ATP
Item
Appearance
A white to off-white powder
Conforms
Identification
IR
Conforms
PH
2.5-3.5
3.03
Loss on drying
≤ 12.0%
7.72%
Fe+
≤ 0.001%
Conforms
Chloride (Cl)
≤ 0.05%
Conforms
Heavy metals
≤ 10
ppm
Conforms
Assay
≥ 99%
99.2%
Conclusion
The sample conforms to standard
Specification
Results
Usage |
Function and efficacy:
Adenosine triphosphate disodium is a nucleotide derivative involved in the metabolism of fat, protein, sugar, nucleic acid and nucleotides in the body. When the body needs energy for absorption, secretion, muscle contraction and biochemical synthesis reactions, adenosine triphosphate is decomposed into adenosine diphosphate and phosphate groups, and energy is released at the same time. Adenosine disodium triphosphate can penetrate the blood-cerebrospinal fluid barrier, improve the stability and reconstruction ability of nerve cell membranous structure, and promote the regrowth of neurites. This product and pentose can synthesize nucleic acid under the action of enzymes in vivo; and with phospholipid cholamine under the action of transcytidase, it can synthesize cephalin and cytidine monophosphate.
Indications:
Adjuvant therapy for progressive muscular atrophy, sequelae of cerebral hemorrhage, cardiac insufficiency, myocardial disease and hepatitis.
Combination efficacy:
Compound injection prepared with coenzyme A is used for hepatitis, nephritis, heart failure, etc.
Other effects:
Rapid supraventricular tachycardia, asthenopia, ophthalmoplegia, retinal hemorrhage, central retinitis, optic neuritis, optic atrophy.
*Products under the patent are only for R&D use